tbuckley/cabot-search huggingface dataset:
Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial
Authors: Galina Velikova, Linda Jane Williams, Sarah Willis, J Michael Dixon, Juliette Loncaster, Matthew Hatton, Jacqueline Clarke, Ian H Kunkler, Nicola S Russell, A Alhasso, D Adamson, H Algurafi, R Allerton, C Anandadas, A Bahl, L Barraclough, P Barrett-Lee, U Barthakur, C Bedi, M Beresford, J Bishop, G Blackman, P Bliss, D Bloomfield, M Blunt, T Branson, L Brazil, A Brunt, A Chakrabarti, A Chittalie, M Churn, J Clarke, S Cleator, P Crellin, F Danwata, S De-Silva-Minor, A Dhadda, A Eicholz, I Fernando, J Forrest, J Fraser, K Geropantas, A Goodman, R Grieve, M Griffin, M Hadaki, A Hall, M Hatton, J Hicks, S Hignett, M Hogg, R Jyothirmayi, M Khan, S Kumar, P Lawton, D Lee, C Lewinski, C Lim, I Locke, J Loncaster, G Lumsden, S Lupton, B Magee, J Marshall, S Masinghe, C McGregor, M McLennan, P Memtsa, D Milanovic, V Misra, N Mithal, MB Mukesh, A Neal, S Needleman, M Persic, M Quigley, S Raj, P Riddle, D Ritchie, F Roberts, P Robson, H Roe, M Rolles, N Shah, R Sharma, E Sherwin, P Simmonds, G Skailles, S Skaria, W Soe, R Sripadam, A Stevens, A Stockdale, N Storey, N Storey, I Syndikus, N Thorp, N Thorp, S Upadhyay, M Varughese, N Walji, R Welch, T Wells, V Wolstenholme, V Wolstenholme, P Woodings, F Yuille
Journal: The Lancet Oncology (2018)
Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: The circulating cell-free genome atlas (CCGA) study
Authors: M.C. Liu, E. Klein, E. Hubbell, T. Maddala, A.M. Aravanis, J.F. Beausang, D. Filippova, S. Gross, A. Jamshidi, K. Kurtzman, L. Shen, N. Zhang, O. Venn, J. Yecies, S. Patel, D.A. Smith, T. Yeatman, M. Seiden, A.-R. Hartman, G. Oxnard
Journal: Annals of Oncology (2018)
Profilin-1 modulates proliferation and survival of breast cancer cells
Authors: Li Zou, Tuhin Das, Yongho Bae, Alan Wells, Partha Roy
Journal: Cancer Research (2008)

2600  Objective: Profilin-1 (Pfn1) expression is down-regulated in several different types of adenocarcinoma (breast, pancreas, hepatic) and over-expression of Pfn1 completely suppresses tumorigenicity of breast cancer cell lines in xenograft-based animal models therefore implying that Pfn1 is a tumor-suppressor protein. The objective of the present work is to elucidate the cellular and molecular basis underlying Pfn1’s tumor-suppressive action. Methods: MDA-MB-231 breast cancer cell lines stably expressing either GFP (control) or GFP-Pfn1 were used in the present study. Results: Consistent with their failure to induce tumor formation in xenograft models, GFP-Pfn1 expressing cells displayed dramatically reduced proliferation and increased susceptibility to TNF-induced apoptosis when compared to either parental or GFP-expressers. Immunoblot analyses of cell-cycle markers demonstrated a significant up-regulation in the level of p27kip1, a major cyclin-dependent kinase inhibitor, in Pfn1 over-expressing cells. Furthermore, Pfn1 over-expression decreases the activation of AKT (a PIP3-dependent process that is central to the regulation of cell proliferation and survival) in MDA-MB-231 cells. Consistent with this biochemical finding, we found that Pfn1 over-expressing cells displayed a nearly 2-fold reduction in the fluorescence intensity of PIP3 immunostaining compared to control cells thus suggesting for the first time that perturbing Pfn1 can modulate phosphoinositide-dependent signaling in breast cancer cells. Conclusion: Overall, these results indicate that tumor-suppressive action of Pfn1 for breast cancer cells could be linked to its modulation of both cell proliferation and survival pathways.
Abstract 20436: Time-Restricted Feeding Prevents Obesity, but not Atherosclerosis in Apoe-Deficient Mice Fed High Fat Diet
Authors: Mariko Domae, Kenichi Inoue, Teruo Inoue
Journal: Circulation (2016)

Introduction: Perturbation of circadian rhythms has divergent malinfluence in metabolic and cardiovascular responses, causes obesity and hypertension. It has shown that metabolic stress induced by ...
Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)
Authors: M.D. Galsky, R. Banchereau, E.E. Kadel, T. Ramirez-Montagut, S. Mariathasan, A. Thåström, J. Rosenberg, T. Powles, M.S. van der Heijden, A. Necchi
Journal: Annals of Oncology (2018)
Neonatal Tbr1 Dosage Controls Cortical Layer 6 Connectivity
Authors: Siavash Fazel Darbandi, Sarah E. Robinson Schwartz, Qihao Qi, Rinaldo Catta-Preta, Emily Ling-Lin Pai, Jeffrey D. Mandell, Amanda Everitt, Anna Rubin, Rebecca A. Krasnoff, Sol Katzman, David Tastad, Alex S. Nord, A. Jeremy Willsey, Bin Chen, Matthew W. State, Vikaas S. Sohal, John L.R. Rubenstein
Journal: Neuron (2018)
Splenosis of the Liver Capsule
Authors: Emine Budak, Aylin Oral, Bulent Yazici, Ezgi Guler, Ozgur Omur
Journal: Clinical Nuclear Medicine (2018)

Splenosis, a form of ectopic splenic tissue, is generally caused by heterotopic autotransplantation of splenic tissues after traumatic splenic rupture or splenectomy. The implants are often localized intraperitoneally, mostly in the left upper quadrant and splenic region. Hepatic foci are seen only on rare occasions. The differential diagnosis of splenosis foci from malignant masses can be challenging by conventional imaging and lead to unnecessary invasive procedures. This manuscript presents radiological and scintigraphic images of splenosis foci located in the peritoneal cavity and liver capsule of a 46-year-old man who underwent splenectomy due to traumatic splenic rupture 30 years ago.
Farmhouse-like indoor microbiota protects children from asthma also away from farms
Authors: P. Kirjavainen, A. M. Karvonen, M. Taubel, R. Adams, B. Jayaprakash, M. Roponen, H. Renz, P. Pfefferle, B. Schaub, S. Remes, A. Hyvarinen, R. Lauener, Erika von Mutius, J. Pekkanen
Journal: Allergy (2017)
ACR–ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer
Authors: Bital Savir-Baruch, Kevin P. Banks, Jonathan E. McConathy, Olga P. Molchanova-Cook, Ephraim E. Parent, Amol Takalkar, Mark Tulchinsky, Jian Q. Yu, Rathan M. Subramaniam, David M. Schuster
Journal: Clinical Nuclear Medicine (2018)

Abstract The American College of Radiology (ACR) and American College of Nuclear Medicine (ACNM) collaborated to develop a clinical practice document for the performance of fluciclovine positron-emission tomography (PET) / computed tomography (CT) in the evaluation of patients with suspected prostate cancer recurrence based on the elevation of prostate-specific antigen (PSA) level (biochemical recurrence) after prior therapy. Prostate cancer is the third leading cause of cancer death in the United States. Up to 50% of patients diagnosed with prostate cancer will develop biochemical failure after initial therapy. The differentiation of local from extraprostatic recurrence plays a critical role in patient management. The use of functional imaging targeting features of cancer metabolism has proven highly useful in this regard. Amino acid transport is upregulated in prostate cancer. Fluciclovine ( anti -1-amino-3-F-18-fluorocyclobutane-1-carboxylic acid, FACBC, Axumin™) is an artificial amino acid PET tracer which demonstrates utility in the diagnosis of recurrent prostate cancer with significant added value to conventional imaging.
RETRACTED ARTICLE: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease
Authors: Haichen Niu, Lingyu Shen, Tongzhou Li, Chao Ren, Sheng Ding, Lei Wang, Zhonghai Zhang, Xiaoyu Liu, Qiang Zhang, Deqin Geng, Xiujuan Wu, Haiying Li
Journal: Translational Neurodegeneration (2018)

Abstract Background Parkinson’s disease (PD) is a neurodegenerative disease characterized by intraneuronal Lewy Body (LB) aggregates composed of misfolded alpha-synuclein (α-syn). The spread of misfolded α-syn follows a typical pattern: starting in the olfactory bulb (OB) and the gut, this pathology is followed by the progressive invasion of misfolded α-syn to the posterior part of the brain. It is unknown whether the administration of human mutant alpha-synuclein (hm-α-syn, a human mutation which occurs in familial PD) into the OB of rats would trigger similar α-syn propagation and subsequently cause pathological changes in broader brain fields associated to PD and establish an animal model of prodromal PD. Methods hm-α-syn was overexpressed in the OB of rats with an AAV injection. Then motor and non-motor symptoms of the SD rats were tested in different behavioral tasks following the AAV injection. In follow-up studies, pathological mechanisms of α-syn spread were explored at the histological, biochemical and micro-structure levels. Results The experimental results indicated that hm-α-syn was overexpressed in the OB 3 weeks after the AAV injection. 1) overexpression of the Hm-α-syn in the OB by the AAV injection could transfer to wider adjacent fields beyond the monosynaptic scope. 2) The number of tyrosine hydroxylase positive cells body and fibers was decreased in the substantia nigra (SN) 12 weeks after AAV injection. This was consistent with decreased levels of the DA neurotransmitter. Importantly, behavioral dysfunctions were found that included olfactory impairment after 3 weeks, motor ability impairment and decreased muscular coordination on a rotarod 6 weeks after the AAV injection.3) The morphological level studies found that the Golgi staining revealed the number of neuronal branches and synapses in the OB, prefrontal cortex (PFC), hippocampus (Hip) and striatum caudate putamen (CPU) were decreased. 4) phosphorylated α-syn, at Ser-129 (pSer129), was found to be increased in hm-α-syn injected animals in comparison to controls that overexpressed GFP alone, which was also found in the most of LB stained by the thioflavine S (ThS) in the SN field. 5) A marker of autophagy (LC3B) was increased in serval fields, which was colacolizated with a marker of apoptosis in the SN field. Conclusions These results demonstrate that expression of exogenous mutant α-syn in the OB induces pathological changes in the sensitive brain fields by transferring pathogenic α-syn to adjacent fields. This method may be useful for establishing an animal model of prodromal PD.
Short- and Long-Term Prognostic Relevance of Cardiogenic Shock in Takotsubo Syndrome
Authors: Manuel Almendro-Delia, Iván J. Núñez-Gil, Manuel Lobo, Mireia Andrés, Oscar Vedia, Alessandro Sionis, Ana Martin-García, María Cruz Aguilera, Eduardo Pereyra, Irene Martín de Miguel, José A. Linares Vicente, Miguel Corbí-Pascual, Xavier Bosch, Oscar Fabregat Andrés, Alejandro Sánchez Grande Flecha, Alberto Pérez-Castellanos, Javier López Pais, Manuel De Mora Martín, Juan María Escudier Villa, Roberto Martín Asenjo, Marta Guillen Marzo, Ferrán Rueda Sobella, Álvaro Aceña, José María García Acuña, Juan C. García-Rubira, J. Figueras, J.A. Barrabes, M. Andrés, I.J. Núñez Gil, H.D. Mejía, O. Vedia, Gisela Feltes, F. Worner, R. Bascompte Claret, E. Pereyra, J. Jiménez Candil, M.J. García Sánchez, A.C. Martín García, A. Martín García, V. Bodi, C. Bonanad, T. Bastante, M. Cruz Aguilera, J. Palazuelos, D. Sancho Carmona, J. López Pais, J.J. Alonso, M. Almendro Delia, M. Lobo, S. Rodríguez de Leiras, J.C. García Rubira, M. Corbí-Pascual, J.G. Córdoba Soriano, M. De Mora Martín, B. Pérez, R. Martín Asensio, F. Rueda Sobella, I. Santos Pardo, M.C. Manzano Nieto, J.M. Escudier Villa, O. Fabregat Andrés, F. Ridocci-Soriano, M.N. Parias Ángel, H.P. Gaebelt, A. Aceña, R. Martin Reyes, C. Bergua, P. Sanz Puértolas, I. Echeverria Lucotti, R. Vidal Pérez, A. Sionis, A. Duran Cambra, J. Tómas Ortiz, X. Bosch Genover, M. Guillen Marzo, R.A. Bardají, J.M. García Acuña, A. Sánchez Grande Flecha, M.J. García González, G. García de la Villa Redondo, A. Pérez Castellanos, J. Piqueras-Flores, L. Ruíz Valdepeas Herrero, J.A. Linares Vicente, J.R. Ruiz Arroyo, J. García, J.A. Giner Caro, M. Martínez Selles, I. Martín de Miguel
Journal: JACC Heart Failure (2018)
Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival
Authors: Flóra John, Edit Bosnyák, Natasha L Robinette, Alit J Amit-Yousif, Geoffrey R Barger, Keval D Shah, Sharon K Michelhaugh, Neil V Klinger, Sandeep Mittal, Csaba Juhász
Journal: Neuro-Oncology (2018)

Although glioblastomas are heterogeneous brain-infiltrating tumors, their treatment is mostly focused on the contrast-enhancing tumor mass. In this study, we combined conventional MRI, diffusion-weighted imaging (DWI), and amino acid PET to explore imaging-defined glioblastoma subregions and evaluate their potential prognostic value. Contrast-enhanced T1, T2/fluid attenuated inversion recovery (FLAIR) MR images, apparent diffusion coefficient (ADC) maps from DWI, and alpha-[11C]-methyl-L-tryptophan (AMT)-PET images were analyzed in 30 patients with newly diagnosed glioblastoma. Five tumor subregions were identified based on a combination of MRI contrast enhancement, T2/FLAIR signal abnormalities, and AMT uptake on PET. ADC and AMT uptake tumor/contralateral normal cortex (T/N) ratios in these tumor subregions were correlated, and their prognostic value was determined. A total of 115 MRI/PET-defined subregions were analyzed. Most tumors showed not only a high-AMT uptake (T/N ratio > 1.65, N = 27) but also a low-uptake subregion (N = 21) within the contrast-enhancing tumor mass. High AMT uptake extending beyond contrast enhancement was also common (N = 25) and was associated with low ADC (r = −0.40, P = 0.05). Higher AMT uptake in the contrast-enhancing tumor subregions was strongly prognostic for overall survival (hazard ratio: 7.83; 95% CI: 1.98–31.02, P = 0.003), independent of clinical and molecular genetic prognostic variables. Nonresected high-AMT uptake subregions predicted the sites of tumor progression on posttreatment PET performed in 10 patients. Glioblastomas show heterogeneous amino acid uptake with high-uptake regions often extending into non-enhancing brain with high cellularity; nonresection of these predict the site of posttreatment progression. High tryptophan uptake values in MRI contrast-enhancing tumor subregions are a strong, independent imaging marker for longer overall survival.
Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms
Authors: L. Apostolidis, S. Kreutzfeldt, M. Oles, L. Gieldon, C. Heining, P. Horak, B. Hutter, M. Fröhlich, B. Klink, M. Lamping, S. Uhrig, A. Stenzinger, E.C. Winkler, B. Wiedenmann, D. Jäger, E. Schröck, U. Keilholz, M.E. Pavel, H. Glimm, S. Fröhling
Journal: Annals of Oncology (2018)
Corneal Edema and Opacification Preferred Practice Pattern®
Authors: Marjan Farid, Michelle K. Rhee, Esen K. Akpek, Guillermo Amescua, Francisco J. Garcia-Ferrer, Amy Lin, Divya M. Varu, David C. Musch, Francis S. Mah, Steven P. Dunn
Journal: Ophthalmology (2018)
Abstract 18683: Cerebrovascular Accidents in Ebstein's Anomaly: More Paradoxical Embolism, Less Atrial Arrhythmias?
Authors: Nicholas Y Tan, Christine Attenhofer-Jost, Murray D Polkinghorne, Emily R Vargas, David O Hodge, Joseph A Dearani, Heidi M Connolly, Samuel J Asirvatham, Christopher J McLeod
Journal: Circulation (2017)

Introduction: Ebstein’s anomaly (EA), characterized by tricuspid valve and right-sided atrioventricular dysplasia, has been associated with a high incidence of interatrial shunts and increased risk...
Properdin binds independent of complement activation in an in vivo model of anti–glomerular basement membrane disease
Authors: Joseph O’Flynn, Juha Kotimaa, Ria Faber-Krol, Karin Koekkoek, Ngaisah Klar-Mohamad, Angela Koudijs, Wilhelm J. Schwaeble, Cordula Stover, Mohamed R. Daha, Cees van Kooten
Journal: Kidney International (2018)
GW29-e0887 Differential regulation of mitochondrial elongation in cardiac conditioning strategies
Authors: Nur Izzah Ismail, Khairunnisa Katwadi, Xiu Yi Kwek, Mim Mim Lim, Belinda Murphy, Sang Ging Ong, Derek Hausenloy, Sang Bing Ong
Journal: Journal of the American College of Cardiology (2018)
Mediastinal Remnant Thymic Tissue Misdiagnosed as Ectopic Parathyroid Hyperplasia in Secondary Hyperparathyroidism
Authors: Jun Zhang
Journal: Clinical Nuclear Medicine (2018)

A 56-year-old woman with secondary hyperparathyroidism was referred for preoperative localization of hyperfunctioning parathyroid lesions. Tc-MIBI dual-phase and SPECT/CT parathyroid scan showed multiple focal activities behind the thyroid and in the anterior mediastinum, diagnosed as parathyroid hyperplasia. However, the histopathological findings proved them to be hyperplastic parathyroid glands and remnant thymic tissue after parathyroidectomy and unnecessary thoracotomy, respectively.
Gain-of-function <i>IKBKB</i> mutation causes human combined immune deficiency
Authors: Chelisa Cardinez, Bahar Miraghazadeh, Kay Tanita, Elizabeth da Silva, Akihiro Hoshino, Satoshi Okada, Rochna Chand, Takaki Asano, Miyuki Tsumura, Kenichi Yoshida, Hidenori Ohnishi, Zenichiro Kato, Masahide Yamazaki, Yusuke Okuno, Satoru Miyano, Seiji Kojima, Seishi Ogawa, T. Daniel Andrews, Matthew A. Field, Gaetan Burgio, Tomohiro Morio, Carola G. Vinuesa, Hirokazu Kanegane, Matthew C. Cook
Journal: The Journal of Experimental Medicine (2018)

Genetic mutations account for many devastating early onset immune deficiencies. In contrast, less severe and later onset immune diseases, including in patients with no prior family history, remain poorly understood. Whole exome sequencing in two cohorts of such patients identified a novel heterozygous de novo IKBKB missense mutation (c.607G&amp;gt;A) in two separate kindreds in whom probands presented with immune dysregulation, combined T and B cell deficiency, inflammation, and epithelial defects. IKBKB encodes IKK2, which activates NF-κB signaling. IKK2V203I results in enhanced NF-κB signaling, as well as T and B cell functional defects. IKK2V203 is a highly conserved residue, and to prove causation, we generated an accurate mouse model by introducing the precise orthologous codon change in Ikbkb using CRISPR/Cas9. Mice and humans carrying this missense mutation exhibit remarkably similar cellular and biochemical phenotypes. Accurate mouse models engineered by CRISPR/Cas9 can help characterize novel syndromes arising from de novo germline mutations and yield insight into pathogenesis.
Abstract P097: Consumption of Branched Chain Amino Acids and Risk of Coronary Heart Disease in US Men and Women
Authors: Qibin Qi, Kathryn Rexrode, Eric Rimm, Walter Willett, JoAnn Manson, Frank Hu, Lu Qi
Journal: Circulation (2013)

Background Plasma concentrations of branched chain amino acids (BCAAs; valine, leucine, and isoleucine) have recently been associated with risk factors for coronary heart disease (CHD), including obesity and type 2 diabetes. Diet is the only source of these essential amino acids in humans. However, it is unknown whether dietary BCAA intake is associated with risk of CHD. Methods and Results The present study included 74,275 women and 44,421 men from two prospective cohorts: the Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) who were free of diagnosed cardiovascular disease, diabetes or cancer at baseline. We documented 3,060 incident CHD events (including nonfatal myocardial infarction and fatal CHD) during 24 years follow-up of the NHS and 4,128 incident CHD events during 22 years follow-up of the HPFS. BCAA intake was calculated by summing intakes of valine, leucine, and isoleucine estimated from food frequency questionnaires obtained every 4 years. After adjustment for age, ethnicity, smoking, physical activity, alcohol consumption, family history of myocardial infarction, history of hypertension and hypercholesterolemia, aspirin use, menopausal status (women only), glycemic load, intakes of total energy, cereal fiber, fruits, vegetables, saturated fat, polyunsaturated fat and trans fat, BCAA intake was significantly associated with increased risk of CHD in women (for highest vs lowest quintiles of BCAA intake, hazard ratio [HR] = 1.40 [95% CI 1.21-1.62]; P for trend &lt;0.001), men (HR = 1.15 [1.02-1.29]; P for trend =0.01) and combined by meta-analysis (HR = 1.24 [1.13-1.36]; P for trend &lt;0.001). Adjustment for body mass index and diabetes status attenuated the association but the result remained significant in the combined samples (HR = 1.13 [1.04-1.24] for highest vs lowest quintiles of BCAA intake; P for trend =0.008). In separate analyses, intakes of individual BCAA (leucine, isoleucine, and valine) were each associated with increased risk of CHD. Conclusions Our data suggest that higher consumption of BCAAs is associated with moderately increased risk of CHD in women and men and the association is partly explained by obesity and diabetes status.
Incidence of primary graft dysfunction after lung transplantation is altered by timing of allograft implantation
Authors: Peter S Cunningham, Robert Maidstone, Hannah J Durrington, Rajamayier V Venkateswaran, Marcelo Cypel, Shaf Keshavjee, Julie E Gibbs, Andrew S Loudon, Chung-Wai Chow, David W Ray, John F Blaikley
Journal: Thorax (2018)

The importance of circadian factors in managing patients is poorly understood. We present two retrospective cohort studies showing that lungs reperfused between 4 and 8 AM have a higher incidence (OR 1.12; 95% CI 1.03 to 1.21; p=0.01) of primary graft dysfunction (PGD) in the first 72 hours after transplantation. Cooling of the donor lung, occurring during organ preservation, shifts the donor circadian clock causing desynchrony with the recipient. The clock protein REV-ERBα directly regulates PGD biomarkers explaining this circadian regulation while also allowing them to be manipulated with synthetic REV-ERB ligands.
Sixty seconds on . . . hospital car parking
Authors: Abi Rimmer
Journal: BMJ (2018)

NHS Digital has published data showing exactly how much money hospitals in England make from charging for parking.1 Last year NHS trusts made £69.5m from charging staff to park and a further £156.8m from charging patients and visitors.

It does seem rather a lot, although the charges vary by hospital. For example, it costs staff £2 an hour to park at the Royal …
Vascular damage and pulmonary function in very long-term survivors of testicular cancer (TC) treated with cisplatin-based chemotherapy (CT)
Authors: J. Stelwagen, S. Lubberts, L.C. Steggink, G. Steursma, L.M. Kruyt, J.W. Donkerbroek, A.M. van Roon, A.I. van Gessel, S.C. van de Zande, C. Meijer, J.B. Wempe, C.H. Gräfin zu Eulenburg, J. Nuver, A.M.E. Walenkamp, J.D. Lefrandt, J.A. Gietema
Journal: Annals of Oncology (2018)
Localablative treatment for synchronous oligometastatic lung cancer: A propensity score analysis of 180 patients
Authors: N. Frost, A. Tessmer, A. Schmittel, V. van Laak, S. Ochsenreither, B. Temmesfeld-Wollbrück, B. Schmidt, N. Suttorp, M. Witzenrath, C. Grohe
Journal: Annals of Oncology (2018)